New cocktail of drugs and procedure aims to stop liver cancer in its tracks

NCT ID NCT07150377

Not yet recruiting Disease control Sponsor: The Second Affiliated Hospital of Shandong First Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and a procedure that blocks the tumor's blood supply (TACE) in 41 people with advanced liver cancer. The goal is to see if this mix can keep the cancer from growing longer than current treatments. Participants will be divided into two groups: those who have never had systemic therapy and those who have had prior treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iparomlimab, tuvonralimab, lenvatinib, and transarterial chemoembolization (TACE)
What this could lead to: If successful, this combination could offer a new treatment option to slow or shrink advanced liver cancer, potentially extending life without the disease getting worse.
What could go wrong: This is a small, early-phase trial with no control group, so results may not be definitive. The combination of drugs and TACE may cause significant side effects, and the benefit over standard care is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.